<?xml version="1.0" encoding="UTF-8"?>
<p id="Par49">The primary objective is to assess the effect of escalating doses of a 1:1 THC/CBD cannabinoid preparation against placebo on total symptom score at day 14 as measured by the Edmonton Symptom Assessment Scale (ESAS) (change in score from baseline). Secondary objectives are to establish a patient-determined effective dose of a 1:1 THC/CBD formulation and assess the effect on symptom scores at days 7, 21 and 28. Other secondary objectives include assessing the change in total physical and emotional sores, global impression of change, anxiety and depression, opioid use and quality of life at the same time points and to document adverse effects associated with cannabinoid use.</p>
